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Symposium
The Role of Law in the Debate over
Return of Research Results and
Incidental Findings: The Challenge of
Developing Law for Translational Science
Susan M. Wolf*
I. THE THREAT OF LAW
The debate over return of individual results and incidental
findings to human beings who participate in research or whose
specimens and data are used is haunted by law. The
recommendations that have emerged so far in this contentious
debate typically refer in the United States to the framework set
by the federal regulations on human subjects research, federal
law and regulations on privacy, and the federal rules on the
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certification of laboratories to offer test results for use in
clinical care.1 Some commentators have ventured into state law
on human subjects research, privacy, and ownership and
control of specimens and data.2 But all of this gives little
comfort. There is no law directly on point.3 The federal research
regulations say nothing explicitly as yet about incidental
findings or return of individual research results. The privacy
regulations are equally silent. And the Centers for Medicare &
Medicaid Services (CMS), which administers the key federal
law on laboratory quality, has issued no official statement or
rule.4 To date, no reported legal case has been discovered that
addresses return of results or incidental findings in the domain
of research.
Some commentators have taken this as occasion to worry
1. See, e.g., Susan M. Wolf et al., Managing Incidental Findings in
Human Subjects Research: Analysis and Recommendations, 36 J.L. MED. &
ETHICS 219 (2008); Richard R. Fabsitz et al., Ethical and Practical Guidelines
for Reporting Genetic Research Results to Study Participants: Updated
Guidelines from an NHLBI Working Group, 3 CIRCULATION: CARDIOVASCULAR
GENETICS 574-80 (2010); Susan M. Wolf et al., Managing Research Results
and Incidental Findings in Genomic Research Involving Biobanks & Archived
Datasets, 14 GENETICS MED. 361 (2012).
2. See, e.g., Leili Fatehi & Ralph Hall, Enforcing the Rights of Human
Sources to Informed Consent and Disclosures of Incidental Findings from
Biobanks and Researchers: State Mechanisms in Light of Broad Regulatory
Failure, 13 MINN. J. L. SCI. & TECH. 575 (2012).
3. Cf. Ellen Wright Clayton & Amy L. McGuire, The Legal Risks of
Returning Results of Genomic Research, 14 GENETICS MED. 473, 475 (2012)
(“There is no legislation requiring disclosure of research results…. [and] no
lawsuits have found investigators liable for failing to provide such
information….”). For additional legal analyses prior to this symposium that
address return of results and incidental findings under U.S. law, see, e.g.,
Susan M. Wolf, Incidental Findings in Neuroscience Research: A Fundamental
Challenge to the Structure of Bioethics and Health Law, in THE OXFORD
HANDBOOK OF NEUROETHICS 623-34 (Judy Illes & Barbara J. Sahakian eds.,
2011); Henry T. Greely, The Uneasy Ethical and Legal Underpinnings of
Large-Scale Genomic Biobanks, 8 ANN. REV. GENOMICS & HUM. GENETICS 343
(2007); Alan C. Milstein, Research Malpractice and the Issue of Incidental
Findings, 36 J.L. MED. & ETHICS 356 (2008); Anne Marie Tassé, The Return of
Results of Deceased Research Participants, 39 J.L. MED. & ETHICS 621 (2011);
Stacey A. Tovino, Incidental Findings: A Common Law Approach, 15
ACCOUNTABILITY RES.: POLICIES & QUALITY ASSURANCE 242 (2008); Susan M.
Wolf, Jordan Paradise & Charlisse Caga-anan, The Law of Incidental
Findings in Human Subjects Research: Establishing Researchers’ Duties, 36
J.L. MED. & ETHICS 361 (2008).
4. Some CMS officials have graciously presented at meetings and
conferences on this issue, but such presentations do not have the status and
force of a rule.
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about lurking legal liability. It appears to be little reassurance
that no court, to my knowledge, has yet found anyone liable for
mishandling return of results or incidental findings in the
context of human subjects research. Indeed, no one has
apparently even been sued. Yet already, we see views
expressed that researchers must navigate between legal
threats on both sides – liability for failure to return findings on
one side, and liability for wrongly returning on the other. Faced
with the specter of this Scylla and Charybdis, it is small
wonder that researchers are already showing anxiety.
This symposium can play an important role, offering eight
articles on different aspects of law, ethics, and practice. These
articles grew out of a two-year project funded by the National
Human Genome Research Institute (NHGRI) at the National
Institutes of Health (NIH).5 This project was the second in
what has become a trajectory of research efforts on return of
results and incidental findings at the University of Minnesota’s
Consortium on Law and Values in Health, Environment & the
Life Sciences.6 Our first grant, the first NIH-funded grant to
our knowledge whose focus was on this return of results
question, analyzed the approach to incidental findings in
imaging and genetics research. Our second grant—which
supported development of this symposium in the Minnesota
Journal of Law, Science & Technology (MJLST)—has analyzed
how to handle incidental findings and individual research
results in large-scale genomic research involving biobanks and
archived data sets. Our third grant, awarded last year, is
concentrating on the cutting-edge question of return of findings

5. NIH, NHGRI grant #2-R01-HG003178 on “Managing Incidental
Findings and Research Results in Genomic Biobanks & Archives” (Wolf,
Principal Investigator; Kahn, Lawrenz & Van Ness, Co-Investigators) (200911).
6. That trajectory includes NIH, NHGRI grant #2-R01-HG003178 on
“Managing Incidental Findings in Human Subjects Research” (Wolf, Principal
Investigator; Kahn, Lawrenz, Nelson & Paradise, Co-Investigators) (2005-07);
NIH, NHGRI grant #2-R01-HG003178 on “Managing Incidental Findings and
Research Results in Genomic Biobanks & Archives” (Wolf, Principal
Investigator; Kahn, Lawrenz & Van Ness, Co-Investigators) (2009-11); and
NIH, National Cancer Institute (NCI) & NHGRI grant #1-R01-CA154517 on
“Disclosing Genomic Incidental Findings in a Cancer Biobank: An ELSI
Experiment” (Petersen, Koenig & Wolf, Principal Investigators) (2011-16). A
fourth grant recently awarded is a Robert Wood Johnson Foundation
Investigator Award in Health Policy Research on “Translating Research into
Health Benefits: Returning Research Results & Incidental Findings” (Wolf,
Principal Investigator) (2012-14).
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to kin.
This symposium is our second published collection of
articles funded by the NIH grant on return of incidental
findings and research results in large-scale genomic research
involving biobanks and archived data sets. That project
produced a symposium already published in the April 2012
issue of Genetics in Medicine (GIM). The GIM symposium
featured a 26-author consensus recommendations article that is
discussed by many of the articles in this issue of MJLST.7
It is fitting that MJLST devote an issue to this problem.
Concern over law and liability is beginning to loom large in the
debate over return of research results and incidental findings.
Like many cutting-edge issues in biomedicine, resolution of this
one could go seriously astray if anxieties about law and liability
become determinative. This is a familiar dynamic – an issue
emerges in biomedicine; the law is unclear or in transition;
faced with uncertainty, fear of liability and regulatory penalties
begins to erupt; mythology about what law requires gains a
foothold; and resolutions that would be better guided by ethics,
evidence, and established principles of practice, now have to
contend with overblown fears of law. There is a classic
literature on this dynamic.8
Excessive concern with law, especially early in the
development of sound practice and ethical consensus on good
approaches, can stunt the development of appropriate and
effective non-legal norms. Though law and ethics are
sometimes confused, they are distinct. Again, a classic
literature reminds us that law and ethics are indeed different;
in some domains they actually conflict.9 On emerging
7. Wolf et al., Managing Research Results, supra note 1.
8. See, e.g., Emily R. Carrier et al., Physicians’ Fears of Malpractice
Lawsuits Are Not Assuaged by Tort Reforms, 29 HEALTH AFF. 1585 (2010);
Sandra H. Johnson, The Social, Professional, and Legal Framework for the
Problem of Pain Management in Emergency Medicine, 33 J.L. MED. & ETHICS
741 (2005); S. Van McCrary et al., Treatment Decisions for Terminally Ill
Patients: Physicians’ Legal Defensiveness and Knowledge of Medical Law, 20
L. MED. & HEALTH CARE 364 (1992); Alan Meisel, The Legal Consensus About
Forgoing Life-Sustaining Treatment: Its Status and Prospects, 2 KENNEDY
INST. ETHICS J. 309 (1993); Alan Meisel et al., Seven Legal Barriers to End-ofLife Care: Myths, Realities, and Grains of Truth, 284 JAMA 2495 (2000);
Mildred Z. Solomon et al., Decisions Near the End of Life: Professional Views
on Life-Sustaining Treatments, 83 AM. J. PUB. HEALTH 14-23 (1993); David M.
Studdert et al., Medical Malpractice, 350 N. ENG. J. MED. 283 (2004).
9. See, e.g., GEORGE J. ANNAS, STANDARDS OF CARE: THE LAW OF
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biomedical questions, it can be highly adaptive for ethics and
biomedical practice (whether clinical practice or research
practice) to take the lead, exploring and testing potential
approaches. Clarity in the domain of ethics and practice can
support the development of good law. Indeed, sound law in the
world of biomedicine generally supports ethical and competent
practice. In fact, conclusions about what is ethically correct for
the research community and individual researchers in dealing
with return of results and incidental findings is likely to
predate the development of law on these issues.
The goal of this article is to address emerging legal
concerns in the debate over return of results and incidental
findings, clarify what is not at issue, and then make clear the
true nature of the challenge for law. The ultimate purpose of
this analysis is not to discourage work on law, which is surely
needed, but to optimize its contribution to a sound process of
resolution. To shape ethics and practice around premature
conclusions of legal threat would be to thwart an extremely
important debate in research ethics and practice. Much about
law is simply not yet clear in this debate. And this article
suggests that there is a reason for this lack of clarity: neither
the law of research nor the law of clinical care is fully adequate
to govern what is in essence a problem about the translational
process of moving research-derived information into the domain
of clinical care. We need to develop law that is appropriate for
this translational science process. This is a substantial
challenge. We need to seize the opportunity afforded by these
early days of debate to shape and develop law in a way that will
support sound and sustainable answers.
After all, where law works well in biomedicine, it is
because law supports practices that make sense medically,
scientifically, and ethically. Where law threatens to derail
sound research or clinical practice or the translational process
between them, it offers answers that are difficult to defend and
sustain. Law should ultimately support sound resolution of the
issues surrounding return of results and incidental findings.

AMERICAN BIOETHICS (1993); Alexander M. Capron & Vicki Michel, Law and
Bioethics, 27 LOY. L.A. L. REV. 25 (1993); Richard Delgado & P. McAllen, The
Moralist as Expert Witness, 62 B.U. L. REV. 869 (1982); Carl E. Schneider,
Bioethics in the Language of the Law, 24(4) HASTINGS CENT. REP. 16 (1994);
Susan M. Wolf, Law & Bioethics: From Values to Violence, 32 J.L. MED. &
ETHICS 293 (2004); Susan M. Wolf, Ethics Committees in the Courts, 16(3)
HASTINGS CENT. REP. 12 (1986).
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II. EMERGING CONCERNS ABOUT LAW
As work on the law of returning results and incidental
findings gets under way, a few concerns about law are
emerging that warrant careful consideration. More work over
time will be needed on law, to make sure law supports sound
resolution of the issues raised by return of results and
incidental findings. At this early point, one of the biggest
dangers is that fear of law will derail good progress in the
return of results debate. Below are three concerns that have
been voiced as reasons to avoid or minimize return of results
and incidental findings. However, careful examination suggests
that none of these is a compelling reason. There may be other
important reasons to limit return, but these broad legal
concerns should not shut down exploration of return of results
and incidental findings.
A. THE CONCERN THAT ETHICS RECOMMENDATIONS
WILL BE MISTAKEN FOR LAW
Since at least 1999, over a dozen years ago, we have seen
published ethics recommendations on return of results and
incidental findings in research. In 1999, the National Bioethics
Advisory Commission (NBAC) advised returning results only if
“scientifically valid and confirmed,” “the findings have
significant implications for the subjects’ health concerns,” and
“a course of action to ameliorate or treat these concerns is
readily available.”10 In 2001, a project sponsored by the Centers
for Disease Control (CDC) recommended criteria for returning
results in population-based genetic research: “When the risks
identified in the study are both valid and associated with a
proven intervention for risk reduction, disclosure may be
appropriate.”11 In 2004 and 2010, Working Groups sponsored
by the National Heart, Lung, and Blood Institute (NHLBI) at
NIH issued consensus recommendations; the latter specified
when results should be offered and when they may be offered to
research participants.12 In 2005, a Committee of the National
10. NATIONAL BIOETHICS ADVISORY COMMISSION (NBAC), 1 RESEARCH
INVOLVING HUMAN BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY
GUIDANCE 72 (1999).
11. Laura M. Beskow et al., Informed Consent for Population-Based
Research Involving Genetics, 286 JAMA 2315, 2320 (2001).
12. Ebony B. Bookman et al., Reporting Genetic Results in Research
Studies: Summary and Recommendations of an NHLBI Working Group, 140A
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Research Council and Institute of Medicine published
consensus recommendations on return of research results in
human embryonic stem cell research, stating that the duty to
report “depends in large part on the reliability of the findings
and the significance of the information to human health.”13 In
2008, the investigators and Working Group members in our
first project on return of incidental findings published a 21author consensus recommendations article specifying when
incidental findings should be returned, may be returned, and
should not be returned.14 Also in 2008, Caulfield and colleagues
published recommendations on return of results in wholegenome research.15 And earlier this year, we published our
second consensus recommendations paper on return of results
and incidental findings in large-scale genomic research
involving biobanks and archived data sets.16
All of these papers present ethics recommendations. And to
date, not a single one of them appears to have been cited in any
legal decision or used to impose liability. There is a very good
reason for this: ethics is not the same as law. What is
recommended in these papers are general principles, such as
differentiate “should return” from “may return,” plan for and be
careful about the return process, limit return to findings that
are well-understood and actionable, and seek consent from
research participants before returning information. It is widely
recognized that translating such general principles into action
will require a great deal more work. Even devising the roster of
results that are indeed established and actionable will be a
complex and collaborative process. Research is under way to
support specification of the general ethics principles articulated
to date. Indeed, in our latest recommendations paper, we
separated the process of articulating general criteria for return
from the process of analyzing particular findings to decide if
they should be returned.17
AM. J. HUM. GENETICS 1033 (2006); Fabsitz et al., supra note 1.
13. NATIONAL RESEARCH COUNCIL AND INSTITUTE OF MEDICINE
COMMITTEE ON GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH,
GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH 89-90 (2005).
14. Susan M. Wolf et al., Managing Incidental Findings in Human
Subjects Research: Analysis and Recommendations, 36 J.L. MED. & ETHICS
219 (2008).
15. Timothy Caulfield et al., Research Ethics Recommendations for WholeGenome Research: Consensus Statement, 6(3) PLOS BIOL. e73 (2008).
16. Wolf et al., Managing Research Results, supra note 1.
17. Id., at 374-75.
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We would all be kidding ourselves to believe that we had
already generated such consensus across the research
community about return of results and incidental findings and
such specificity about what return should look like that courts
would find an established standard of care. The reality is that
debate, research, and specification are very obviously works in
progress. NIH is playing a crucial role in funding the
significant quantity of research still needed to form an evidence
base for research standards, and linking investigators in a
Return of Results Consortium to advance progress.18 I have
written elsewhere that agreeing on well-supported standards
for the research community will probably require years of
work.19
Another reason to look skeptically on claims that our
current ethics recommendations will generate legal liability is
that the ethics literature to date acknowledges that research
studies vary significantly, as do biobanks and other research
resources. It is highly doubtful that a single policy or standard
will suffice for all. Indeed, our project’s recent ethics
recommendations for biobank research systems recognized
variation in how such systems are structured, whether reidentification of individual participants is possible, and
whether return involves retrofitting a preexisting biobank or
prospectively designing a new one.20 Underscoring this, an
article published in our project’s Special Issue of GIM examined
the approach to return of results across five biobanks that were
all members of the NIH-funded eMERGE Network; the article
documented a wide range of approaches to return of results,
even though all five sites were considering the
recommendations of a joint Return of Results Oversight
Committee.21
It is true that when consensus recommendations to date
consider return of results, they look at a number of informative
18. See Jeannine Mjoseth, NHGRI Funds Return of Results Studies,
Forms Expert Consortium, http://www.genome.gov/27545526 (last visited May
8, 2012).
19. Susan M. Wolf, The Past, Present, and Future of the Debate over
Return of Research Results & Incidental Findings, 14 GENETICS MED. 355
(2012).
20. See Wolf et al., Managing Research Results, supra note 1.
21. Stephanie M. Fullerton et al., Return of Individual Research Results
from Genome-Wide Association Studies: Experience of the Electronic Medical
Records and Genomics (eMERGE) Network, 14 GENETICS MED. 424 (2012).
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sources, including of course the regulations on human subjects
research and sometimes statutes such as the Clinical
Laboratory Improvement Amendments (CLIA) and the Health
Insurance Portability and Accountability Act (HIPAA). Ethics
groups examine these sources to try to inform and reconcile
their recommendations with already-existing rules. That said,
there is no guarantee that ethics groups will find the current
law adequate. There are many examples in the history of
bioethics and medical ethics of ethics authorities and scholars
as well as practicing clinicians finding the law wanting and
even in conflict with sound ethics.22 Because the regulations on
human subjects research, CLIA, and HIPAA were devised with
no attention to the problem of return of results and incidental
findings, we should not be surprised if sustained ethics analysis
finds these legal sources wanting and in need of development or
amendment to adequately address these issues.
B. THE CONCERN THAT RETURN OF RESULTS &
INCIDENTAL FINDINGS MISTAKES RESEARCH
FOR CLINICAL CARE
The claim that return of research results and incidental
findings mistakes research for clinical care restates the
question at the heart of the return of results debate, rather
than providing an answer. The question of whether to return
results and incidental findings from research is a challenging
one precisely because the context is research and not clinical
care. Research is classically defined as the search for
generalizable knowledge.23 Traditionally researchers have
recognized no responsibility to communicate clinically
important information about individuals, with limited
exceptions.24 Both law and ethics have conceived of the
research and clinical spheres as generally quite distinct. The
researcher has been seen as owing limited duties to the
individual research participants, in contrast to the clinician,
22. For examples and an exploration of the relationship of law and
bioethics, see Susan M. Wolf, Law & Bioethics: From Values to Violence, 32
J.L. MED. & ETHICS 293 (2004).
23. This is based on the Common Rule definition of “research” as “a
systematic investigation, including research development, testing and
evaluation, designed to develop or contribute to generalizable knowledge.” 45
C.F.R. § 46.102 (d) (2011).
24. Exceptions would include duties to report “significant new findings
developed during the course of the research which may relate to the subject’s
willingness to continue participation” (45 C.F.R. § 46.116 (b) (5) (2011)).
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who undertakes a broad duty of care toward the individual
patient.
The discovery that research routinely and predictably
generates information of clinical significance to individual
participants, whether in the form of individual research results
or incidental findings, has challenged this traditional
dichotomy between research and clinical care.25 When some
findings have urgent clinical significance (such as
pharmacogenetic findings revealing that the individual may
have a catastrophic reaction to a commonly used drug), the
tradition of researcher silence becomes more difficult to defend.
Indeed, it has become hard to find participants in the return of
results debate who maintain that no individual results or
findings should ever be returned, no matter how clinically
urgent the information. Imaging researchers long ago accepted
responsibility for reporting findings of serious clinical
significance.26 Genetic and genomic researchers have come
more slowly to this acceptance of responsibility, but now are
hard at work fleshing out what it should mean in research
practice.
The literature increasingly offers ethical theories and
argument about the grounding and scope of the responsibility.
But for our purposes here, the key insight is that the research
context is precisely what necessitates this philosophical work.
Were we instead talking about the clinical context, no complex
argument would be needed to support the notion that a
clinician treating malady X who stumbles upon additional
malady Y has a duty to convey that information to the patient,
so that the patient can decide whether and how to address the
newly discovered problem.
The challenge of the return of results debate is that it
forces us to rethink the traditional wall between research and
clinical care, by raising the question of whether researchers
have some informational duties to convey findings of high
clinical significance to the individual participant. This is a deep
challenge to the traditional architecture of both health law and
bioethics, which have largely accepted and built upon a
dichotomy between the two spheres. To restate the difference

25. See Susan M. Wolf, Incidental Findings in Neuroscience Research,
supra note 3.
26. See Wolf et al., Managing Incidental Findings, supra note 1.
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between research and clinical care is no answer to what to do in
the face of this challenge; it merely recapitulates the question.
Just as it is increasingly difficult to find commentators who
argue for no return, no matter how urgent the information, it is
also increasingly difficult to find commentators who argue for
conveying all information derived in the research sphere, at
least at this juncture. Too much of that information still
remains uncertain and even mistaken, to dump it all on
research participants. Thus, the scope of the responsibility to
return is at this point limited. This accounts for the effort in
publication after publication to articulate the criteria that
should be met before return is undertaken.
There is no denying that allowing the traditional wall
between research and clinical care to give way is unsettling.
The wall is starting to resemble something more like a
membrane allowing some kinds of information through. We
remain in the early days of the research required to figure out
what to return and how—the appropriate functioning of this
permeable membrane. But it is no accident that this conceptual
shift is happening now. The rise of a translational concept of
genetics and genomics has brought into focus the precise
process by which research moves into clinical practice.
Increasingly, the goal of research is to move information and
interventions into clinical use. And not just for populations—
individualized or personalized medicine embraces the reality of
individual genetic and genomic difference. When translational
science is combined with personalized medicine, it is inevitable
that researchers have to confront the question of how and when
research information should be offered to individuals because of
that information’s potential clinical significance. Instead of two
domains separated by a wall, research and clinical care have
become part of a spectrum that moves research insights into
clinical use.
In the face of this, to say that the return of results
mistakes research for clinical care is a throwback to a time
before we embraced that continuum, with all of its challenges.
There is no going back to the two-world vision. What has
emerged is more complex and continuous.
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C. THE CONCERN THAT RESEARCH RESULTS &
INCIDENTAL FINDINGS CANNOT MEET STANDARDS
FOR RESPONSIBLE RETURN
There is wide agreement that returning findings to
research participants calls for confidence that the test
performed and information derived have acceptable accuracy,
the clinical implications are understood, and the sample and
data in question indeed belong to this participant. Thus we see
a near-universal demand for analytic validity as a precondition
for informational return.27 A further recommendation has been
that an individual research result or incidental finding has
“established” risk or meaning.28 There is debate about how
established the risk or meaning should be to allow return, and
whether to offer research participants not only findings, but
also information on how well understood and established the
associated risk or meaning is. Yet another recommendation on
the protective standards that should condition return is the
frequently stated—but still somewhat controversial—
requirement that any findings to be returned are generated
and/or confirmed in a CLIA-certified laboratory.29
All of these issues are aspects of a single question: What
standards should apply to govern the quality of information
that is offered to research participants? In addressing this
question, it is important to recognize that notifying research
participants of an incidental finding or individual research
result of concern is typically not suggested as a substitute for
clinical diagnosis and care. In imaging research, for example,
research scans may not be of clinical grade and optimized for
clinical diagnosis. Thus, what research will often generate is
findings and results of potential clinical concern. So the
question is what level of confidence about the finding and its
clinical implications is necessary before sharing this
27. See, e.g., Fabsitz et al., supra note 1, at 575, 578; Wolf et al.,
Managing Return of Results, supra note 1, at 378. In genomic testing,
“analytic validity” refers to “[h]ow accurately and reliably the test measures
the genotype of interest.” “Clinical validity” refers to “[h]ow consistently and
accurately the test detects or predicts the…outcomes of interest.” Centers for
Disease Control and Prevention, Genomic Testing: ACCE Model Process for
Evaluating Genetic Tests, available at http://www.cdc.gov/genomics/gtesting/
ACCE/index.htm (last visited May 3, 2012).
28. See, e.g., Fabsitz et al., supra note 1, at 575.
29. On the CLIA controversy, see, e.g., Fabsitz et al., supra note 1, at 57677; Wolf et al., Managing Return of Results, supra note 1, at 371.
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information in order to trigger the research participant’s
pursuit of definitive clinical diagnosis and care.
To simply say that the standards of clinical testing and
diagnosis should apply wholesale is to avoid what is at the
heart of the return of results and incidental findings debate – a
translational question30 of what research information is
appropriate for return. This is a complex question, whose
answer may vary depending on a range of variables, including
the nature of the research participant population in question,
whether the research participants are healthy volunteers or
individuals affected by a condition they are trying to cope with
and understand, and whether clinical work-up is readily
available once the research-generated information is offered to
trigger that clinical consideration. Returning results and
incidental findings meeting all of the quality standards for
communication in a clinical setting (including findings that are
already routinely communicated in clinical settings) may turn
out to be the easy case. More challenging will be consideration
of other cases, such as cases in which a novel genetic or
genomic abnormality is found with too little literature to say its
meaning is “established,” but raising such concern among
genetics professionals that they consider sharing the
information to contribute to diagnostic efforts that have thus
far been unavailing. This is a scenario that would require
careful and detailed consideration, but is already of concern to
researchers.
II. THE REAL CHALLENGE: DEVISING
TRANSLATIONAL ETHICS, PRACTICE, & LAW
Making progress in the debate over return of research
results and incidental findings requires recognizing that the
debate is fundamentally about the translational process.
Return of information generated in the process of conducting
research, because of the potential clinical importance of that
information, is a practice that occupies the space between
research and clinical care. It does not fit neatly into the
preexisting ethics or law of either research or clinical care. It
30. On translational genomics and translational science more generally,
see, e.g., Muin J. Khoury et al., The Continuum of Translation Research in
Genomic Medicine: How Can We Accelerate the Appropriate Integration of
Human Genome Discoveries into Health Care and Disease Prevention?, 9
GENETICS MED. 665 (2007); Elias A. Zerhouni, Translational and Clinical
Science—Time for a New Vision, 353 N. ENG. J. MED. 1621 (2005).
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lies in the domain between them. There is no escaping that this
translational practice is calling for the development of new
ethical approaches and insights. It similarly calls for the
development of legal standards that fully consider the
translational character and complexities of this practice.
The traditional ethics and law of research (on the one
hand) and clinical care (on the other) are surely relevant to
developing this translational ethics and law. But they were not
developed with careful attention to this problem and are not
adequate to its resolution. The emergence of translational
genomics requires an ethics that is evolving. And it requires
the development of law that addresses the complexities of
translational practices soundly and sustainably. We do not yet
have such law in place. Developing translational law lies
largely ahead of us.31 This symposium aims to contribute to
that effort.

31. For beginning efforts, see, e.g., Gary E. Marchant, Personalized
Medicine and the Law, ARIZONA ATTORNEY, Oct. 2007, at 12, available at
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1469686 (last visited May
8, 2012); Michael Tomasson, Legal, Ethical, and Conceptual Bottlenecks to the
Development of Useful Genomic Tests, 18 ANN. HEALTH L. 231 (2009).

